期刊文献+

VX-680诱导人膀胱癌T24细胞凋亡及其对Bcl-2表达的影响 被引量:4

VX-680 induces apoptosis of T24 human bladder cancer cells and down-regulates Bcl-2 expression
下载PDF
导出
摘要 目的:探讨Aurora A激酶抑制剂VX-680对人膀胱癌T24细胞凋亡的诱导作用及对Bcl-2 mRNA和蛋白表达的影响及意义。方法:体外培养T24细胞,分别给予不同浓度及作用时间的VX-680,Annexin V/PI检测细胞凋亡;Hoechst染色法检测细胞凋亡形态学改变;RT-PCR和Western blot检测细胞Bcl-2 mRNA和蛋白的表达。结果:Annexin V/PI显示,凋亡率分别随着浓度增高和时间增长而增加,呈浓度及时间依赖性;Hoechst染色发现细胞在处理72 h后,其凋亡增多程度及Bcl-2 mRNA和蛋白表达下调水平均随浓度增高而增加,呈浓度依赖性。结论:Aurora激酶抑制剂VX-680可能通过下调Bcl-2表达显著诱导人膀胱癌T24细胞凋亡,且具有浓度依赖性。 Objective To investigate the effect of aurora kinase inhibitor VX-680 on cell apoptosis and Bcl-2 expressions in human bladder cancer T24 cells. Methods T24 cells were cultured and treated with VX-680 at various concentrations and time points in vitro. VX-680-induced apoptosis of T24 cells was calculated by flow cytometry. The morphological change of treated cells was observed by microscopy;Bcl-2 mRNA and protein expression in T24 ceils was detected by RT-PCR and Western blot assay, respectively. Results The apoptosis rate of VX-680-induced T24 cells increased in a dose- and time-dependent manner. The increase of apoptosis rate and decrease of Bcl-2 mRNA and protein expression in VX-680-induced T24 cells were in a dose-dependent manner. Conclusion VX-680 can significantly induce the apoptosis of T24 cells by down-regulating Bcl-2expression in a dose-dependent manner.
出处 《实用医学杂志》 CAS 北大核心 2014年第7期1060-1062,共3页 The Journal of Practical Medicine
基金 广东省科技计划项目(编号:2011B031800030)
关键词 膀胱肿瘤 VX-680 人膀胱癌T24细胞 细胞凋亡 BCL-2 Urinary bladder neoplasms VX-680 Human bladder cancer T24 cell Apoptosis Bcl-2
  • 相关文献

参考文献10

  • 1赫捷,陈万青.膀胱癌-2012年中国肿瘤登记年报[M].北京:军事医学科学出版社,2012:97.
  • 2Sternberg CN, Bellmunt J, Sonpavde G, et al. ICUD-EAU In- ternational Consul -tation on Bladder Cancer 2012: Chemothera- py for ur-othelial carcinoma-neoadju-vant and adjuvant settings [ J ]. Eur Urol, 2013,63 ( 1 ) : 58-66.
  • 3Harrington EA, Bebbington D, Moore J, et al. VX-680, a po- tent and selective small molecule inhibitor of the Aurora kinas- es, suppresses tumor growth in vivo [J~. Nature Med, 2004, 10 ( 3 ) : 262-267.
  • 4Kollareddy M, Zheleva D, Dzubak P, et al. Aurora kinase in- hibitors: progress towards the clinic [J]. Invest New Drugs, 2012,30(6) : 2411-2432.
  • 5Pitts TM, Davis SL, Eckhardt SG, et al. Targeting nuelear ki- nases in cancer: Development of cell cycle kinase inhibitors [ J ]. Phannacol Ther, 2013, [Epub ahead of print].
  • 6Yao R, Zheng J, Zheng W, et al. VX680 suppresses the growth of HepG2 cells and enhances the chemosensitivity to cisplatin [J]. Oncol Lett, 2013,7(1):121-124. T.
  • 7avanti E, Sero V, Vella S, et al. Preclinical validation of Au- rora kinases-targeting drugs in osteosarcoma [J]. Br J Cancer, 2013,109(10) : 2607-2618.
  • 8Habib GM. Arsenite causes down-regulation of Akt and c-Fos, cell cycle dysfunction and apoptosis in glutathione-deficient cell [Jl. J Cell Biochem, 2010, 110(2) :363-371.
  • 9Bangaru ML, Chen S, Woodliff J, et al. Curcumin (diferuloyl- methane) induces apoptosis and blocks migration of human medulloblastoma cells [J]. Anticancer Res, 2010, 30(2) :499- 504.
  • 10Zhang L, Zhang S. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the ehemosensitivity to cisplatin [Jl. J Obstet Gynaecol Res, 2011,37(6) :591-600.

共引文献2

同被引文献41

  • 1谢立平,毛祺琦.膀胱癌发病及影响预后的危险因素[J].临床外科杂志,2009,17(11). 被引量:7
  • 2Kulkami GS, Hakenberg OW, Gschwend JE. An updated criticalanalysis of the treatmentstrategy for newly diagnosed highgradeTl(previously TlG3)bladder cancer[J].EuropeanUrology, 2010, 15(09):378-381.
  • 3Babjuk M, OosterlinckW, Sylvester R. EAU guidelines onnon-muscle-invasive urothelialcarcinoma ofthe bladder,the 2011update[J].European Urology, 2011,32(6): 2316-2319.
  • 4侯睿之.吡格列酮或致膀胱癌恐步文迪雅后尘[N]:中国医药指南.2011-08-16.
  • 5Dalbagni G, Russo P, Sheinfeld J, et al. Phase II trial of intravesicalgemcitabine in bacille Calmette-Gu§ rin-refractory transitional cellcarcinoma ofthe bladder[J].J Clin Oncol, 2006, 24(18): 2729-2734.
  • 6BORRE PV, MCFADDEN DG, GUNDA V, et al. The next generation of orthotopie thyroid cancer models: immunocompetent orthotopic mouse models of BRAFVE-positive papillary and anaplastic thyroid carcinoma [J]. Thyroid, 2014,24 (4) :705 - 714.
  • 7OKADA T, NAKAMURA T, WATANABE T, et al. Coexpression of EpCAM, CD44 variant isoforms and claudin-7 in anaplastic thyroid carcinoma [ J]. PloS One, 2014,9(4) : e94487.
  • 8BALD1NI E, D'ARMIENTO M, UL1SSE S. A new Aurora in anaplastic thyroid cancer therapy [J]. Int J Endocrinol, 2014: 816430.
  • 9DE GROOT CO, HSIA JE, ANZOLA JV, et al. A cell biologist's field guide to Aurora kinase inhibitors [J]. Front Oncol, 2015, 5:285.
  • 10D'ASSORO AB, HADDAD T, GALANIS E. Aurora-a kinase as a promising therapeutic target in cancer [ J ]. Front Oncol, 2016, 5 : 295.

引证文献4

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部